Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis

Expression and prognostic value of the WEE1 kinase in gliomas

(2016) Darija Music et al.   JOURNAL OF NEURO-ONCOLOGY

Assessment of Quantitative and AllelicMGMTMethylation Patterns as a Prognostic Marker in Glioblastoma

(2016) Lasse S. Kristensen et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

(2016) Charlotte Roach et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma

(2015) Veronica Villani et al.   DISEASE MARKERS

High levels of c-Met is associated with poor prognosis in glioblastoma

(2015) Stine Asferg Petterson et al.   JOURNAL OF NEURO-ONCOLOGY

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region

(2014) Manabu Kanemoto et al.   BMC CANCER

MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study

(2014) Dong Shen et al.   PLoS One

Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

(2014) Vincent Peter Collins et al.   Acta Neuropathologica Communications

Exclusion of Histiocytes/Endothelial Cells and Using Endothelial Cells as Internal Reference Are Crucial for Interpretation of MGMT Immunohistochemistry in Glioblastoma

(2013) Chih-Yi Hsu et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Prognostic value of Musashi-1 in gliomas

(2013) Rikke H. Dahlrot et al.   JOURNAL OF NEURO-ONCOLOGY

Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome

(2013) Shadi Lalezari et al.   NEURO-ONCOLOGY

Double-labelling immunohistochemistry for MGMT and a “cocktail” of non-tumourous elements is a reliable, quick and easy technique for inferring methylation status in glioblastomas and other primary brain tumours

(2013) Elinor Burke et al.   Acta Neuropathologica Communications

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

Aberrant Expression of N-Methylpurine-DNA Glycosylase Influences Patient Survival in Malignant Gliomas

(2012) Ce Liu et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

(2012) Annette Håvik et al.   Journal of Translational Medicine

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

(2012) Consolación Melguizo et al.   Journal of Translational Medicine

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

The molecular profile of microglia under the influence of glioma

(2012) W. Li et al.   NEURO-ONCOLOGY

Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma

(2012) Arne Christians et al.   PLoS One

Tumor Microenvironment in the Brain

(2012) Mihaela Lorger   Cancers

High Concordance Between Two Companion Diagnostics Tests

(2011) Jan Trøst Jørgensen et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

O6-Methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma

(2011) Reiko Watanabe et al.   Brain Tumor Pathology

Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue

(2011) Yukie Araki et al.   Brain Tumor Pathology

Heterogeneity Maintenance in Glioblastoma: A Social Network

(2011) R. Bonavia et al.   CANCER RESEARCH

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma

(2011) Miyuki Uno et al.   Clinics

The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour Consortium

(2011) U. Bartels et al.   Current Oncology

The brain tumor microenvironment

(2011) Nikki A. Charles et al.   GLIA

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

(2011) Guido Reifenberger et al.   INTERNATIONAL JOURNAL OF CANCER

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations

(2011) Shani Mulholland et al.   INTERNATIONAL JOURNAL OF CANCER

Glioblastoma cells: A heterogeneous and fatal tumor interacting with the parenchyma

(2011) Tercia Rodrigues Alves et al.   LIFE SCIENCES

Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients

(2011) Kai Tang et al.   MEDICAL ONCOLOGY

Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM

(2011) Nameeta Shah et al.   PLoS One

CD133+ niches and single cells in glioblastoma have different phenotypes

(2010) Karina Christensen et al.   JOURNAL OF NEURO-ONCOLOGY

Astrocytes: biology and pathology

(2009) Michael V. Sofroniew et al.   ACTA NEUROPATHOLOGICA

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

(2009) J Dunn et al.   BRITISH JOURNAL OF CANCER

Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients

(2009) J. Felsberg et al.   CLINICAL CANCER RESEARCH

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

(2009) Lucie Karayan-Tapon et al.   JOURNAL OF NEURO-ONCOLOGY

Flow cytometry and in vitro analysis of human glioma–associated macrophages

(2009) Ian F. Parney et al.   JOURNAL OF NEUROSURGERY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND MGMT PROTEIN IN GLIOBLASTOMAS

(2009) Van Thang Cao et al.   NEUROSURGERY

CD133 identifies perivascular niches in grade II–IV astrocytomas

(2008) Karina Christensen et al.   JOURNAL OF NEURO-ONCOLOGY

Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours

(2008) V. Häyry et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY